0NF7 Stock Overview
PCAS SA develops and produces complex molecules for life sciences and specialty chemicals markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PCAS SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.05 |
| 52 Week High | €8.05 |
| 52 Week Low | €6.34 |
| Beta | 0.37 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NF7 | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -0.4% |
| 1Y | n/a | -29.6% | 5.6% |
Return vs Industry: Insufficient data to determine how 0NF7 performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how 0NF7 performed against the UK Market.
Price Volatility
| 0NF7 volatility | |
|---|---|
| 0NF7 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 4.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NF7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0NF7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 1,178 | Jean-Louis Martin | www.pcas.com |
PCAS SA develops and produces complex molecules for life sciences and technologies. The company was founded in 1962 and is headquartered in Longjumeau, France. PCAS SA is a subsidiary of Seqens SAS
PCAS SA Fundamentals Summary
| 0NF7 fundamental statistics | |
|---|---|
| Market cap | €109.93m |
| Earnings (TTM) | €8.76m |
| Revenue (TTM) | €229.96m |
12.5x
P/E Ratio0.5x
P/S RatioIs 0NF7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NF7 income statement (TTM) | |
|---|---|
| Revenue | €229.96m |
| Cost of Revenue | €81.51m |
| Gross Profit | €148.45m |
| Other Expenses | €139.69m |
| Earnings | €8.76m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 64.55% |
| Net Profit Margin | 3.81% |
| Debt/Equity Ratio | 2,725.7% |
How did 0NF7 perform over the long term?
See historical performance and comparison